BOSTON SCIENTIFIC CORPORATION Business Acquisition, Pro Forma Revenue
BOSTON SCIENTIFIC CORPORATION (BSX) reported Business Acquisition, Pro Forma Revenue of $11.14 billion for the 12-month period ending 2019-12-31, per its 10-K filed 2020-02-25.
Discontinued › Income Statement › Other Income
us-gaap:BusinessAcquisitionsProFormaRevenue · last filed 2020-02-25
- BOSTON SCIENTIFIC CORPORATION business acquisition, pro forma revenue for the quarter ending 2019-12-31 was $2.90B, a 8.03% increase year-over-year.
- BOSTON SCIENTIFIC CORPORATION business acquisition, pro forma revenue for the quarter ending 2019-09-30 was $2.79B, a 9.14% increase year-over-year.
- BOSTON SCIENTIFIC CORPORATION business acquisition, pro forma revenue for the quarter ending 2018-12-31 was $2.69B.
- BOSTON SCIENTIFIC CORPORATION business acquisition, pro forma revenue for the quarter ending 2018-09-30 was $2.56B.
- BOSTON SCIENTIFIC CORPORATION business acquisition, pro forma revenue for fiscal 2019 was $11.14B, a 6.84% increase from fiscal 2018.
- BOSTON SCIENTIFIC CORPORATION business acquisition, pro forma revenue for fiscal 2018 was $10.43B.
| Period end | Business Acquisition, Pro Forma Revenue 3 month | Business Acquisition, Pro Forma Revenue 6 month | Business Acquisition, Pro Forma Revenue 9 month | Business Acquisition, Pro Forma Revenue 12 month |
|---|---|---|---|---|
| 2019-12-31 | $2.90B derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $5.70B derived: sum of 2 quarters · filed 2020-02-25 | $11.14B 10-K · filed 2020-02-25 | |
| 2019-09-30 | $2.79B 10-Q · filed 2019-11-05 | $8.24B 10-Q · filed 2019-11-05 | ||
| 2018-12-31 | $2.69B derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $5.25B derived: sum of 2 quarters · filed 2020-02-25 | $10.43B 10-K · filed 2020-02-25 | |
| 2018-09-30 | $2.56B 10-Q · filed 2019-11-05 | $7.74B 10-Q · filed 2019-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BECTON DICKINSON & CO (BDX) | United States | $48.834B | 43.79 |
| 3M CO (MMM) | United States | $86.404B | 27.87 |
| DEXCOM INC (DXCM) | United States | $33.004B | 25.42 |
| WEST PHARMACEUTICAL SERVICES INC (WST) | United States | $26.288B | 43.14 |
| STRYKER CORP (SYK) | United States | $103.511B | 32.39 |
| Solventum Corp (SOLV) | United States | $15.085B | 9.16 |
| Penumbra Inc (PEN) | United States | $12.596B | 77.33 |
| BAXTER INTERNATIONAL INC (BAX) | United States | $12.139B | -10.35 |
| GLOBUS MEDICAL INC (GMED) | United States | $9.977B | 20.03 |
| INSULET CORP (PODD) | United States | $9.420B | 28.12 |